Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Heart transplantation--a two-year experience.

R Hetzer, H Warnecke, S Schüler

    Zeitschrift Fur Kardiologie
    |January 1, 1985
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Erratum to: Inhibition of atrial fibrillation by pulmonary vein isolation and auricular resection-experimental study in a sheep model [Eur J Cardiothorac Surg 1997;11:714-21].

    European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery·2017
    Same author

    Effectiveness of protecting a zirconia bonding surface against contaminations using a newly developed protective lacquer.

    Dental materials : official publication of the Academy of Dental Materials·2014
    Same author

    Myocardial metabolic monitoring with the microdialysis technique during and after open heart surgery.

    Acta anaesthesiologica Scandinavica·2007
    Same author

    [An uncommon cause of recurrent abdominal pain in a 63-year-old obese woman].

    Deutsche medizinische Wochenschrift (1946)·2006
    Same author

    [Intravascular ultrasound-guided diagnosis after transmural anterior ischemia and cardiogenic shock].

    Zeitschrift fur Kardiologie·2003
    Same author

    Detection of Helicobacter pylori specific DNA in human atheromatous coronary arteries and its association to prior myocardial infarction and unstable angina.

    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·2002

    Heart transplantation is a viable treatment for end-stage heart failure, offering a 75% survival rate at two years. Effective immunosuppression and rejection monitoring are key to long-term success in cardiac transplant patients.

    Area of Science:

    • Cardiology
    • Transplant Surgery
    • Immunology

    Background:

    • End-stage heart failure necessitates advanced treatment options.
    • Orthotopic heart transplantation emerged as a critical intervention in the 1980s.
    • Patient selection criteria are vital for successful cardiac transplant outcomes.

    Purpose of the Study:

    • To evaluate the early outcomes of a newly established heart transplant program.
    • To identify major challenges and effective management strategies in post-transplant care.
    • To assess the feasibility and survival rates of cardiac transplantation for intractable heart failure.

    Main Methods:

    • Performed 72 orthotopic heart transplants in 69 patients between July 1983 and September 1985.
    • Monitored patients for rejection using serial endomyocardial biopsy and myocardial voltage monitoring.

    Related Experiment Videos

  • Employed a triple immunosuppressive regimen: Azathioprine, Cyclosporine A, and steroids, with initial antithymocyte globulin.

    • Main Results:

    • Overall actuarial survival at one and two years was 75%.
    • Key postoperative challenges included allograft rejection, infection, and graft-versus-host disease.
    • Identified rejection as the primary cause of mortality, followed by infection and cerebrovascular events.

    Conclusions:

    • Heart transplantation is a feasible and effective treatment for end-stage heart failure.
    • A comprehensive immunosuppressive strategy is crucial for long-term allograft survival.
    • Cardiac transplantation should be considered for eligible patients under 55 with life-threatening heart failure unresponsive to other therapies.